Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases.
Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed.
The Eiger management team has extensive experience in the clinical development and commercialization of a broad range of therapeutics, with special expertise in Orphan Designation drugs.
David A. Cory, RPh, MBA
President and Chief Executive Officer, Director, Business Founder
David Cory is an industry veteran with over 25-years of experience in large pharmaceuticals, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record of operational performance, including 5 successful Orphan Designation drug programs.
Cory is President and CEO, Director, and business founder of Eiger BioPharmaceuticals, leading the company since founding and responsible for negotiating the company’s multiple technology and product licenses from Stanford University, Merck, Nippon Kayaku, and Janssen. Previously, Cory was CEO of DiObex, a metabolic disease company. Cory was President and Chief Operating Officer of Prestwick Pharmaceuticals, an Orphan CNS specialty pharmaceutical company, which was acquired by Biovail for $160 million. Cory was Co-Founder and Acting Chief Commercial Officer at CoTherix, an Orphan Pulmonary Arterial Hypertension company, which was acquired by Actelion for $425 million. Cory began his start up career at InterMune, focused on developing Orphan products for Idiopathic Pulmonary Fibrosis, where he was a Senior Vice President, and a key executive in the company IPO, building and managing the company’s commercial organization, in-licensing 4 products and raising over $400 million in the capital markets. InterMune was acquired by Roche for $8 billion. Cory began his large pharma career in operating positions of increasing responsibility at The Upjohn Company, Glaxo, Glaxo Wellcome, and Glaxo Smith Kline where he led teams in CNS, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas, and directed 10 pharmaceutical product launches including Flolan (epoprostenol), the first Orphan Designation therapy approved for Pulmonary Arterial Hypertension.
David Cory earned a BS from the University of Cincinnati, College of Pharmacy and an MBA from the University of Maryland, University College.